Q1 EPS Estimate for Lyell Immunopharma Lifted by Analyst

Lyell Immunopharma, Inc. (NASDAQ:LYEL) – Equities researchers at HC Wainwright boosted their Q1 2025 earnings per share estimates for Lyell Immunopharma in a research report issued to clients and investors on Thursday, March 13th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($0.17) per share for the quarter, up from their prior estimate of ($0.20). HC Wainwright has a “Neutral” rating and a $1.00 price target on the stock. The consensus estimate for Lyell Immunopharma’s current full-year earnings is ($0.78) per share. HC Wainwright also issued estimates for Lyell Immunopharma’s Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.20) EPS and FY2025 earnings at ($0.73) EPS.

Lyell Immunopharma (NASDAQ:LYEL) last issued its earnings results on Wednesday, March 12th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.52). Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. The company had revenue of $0.01 million for the quarter.

Lyell Immunopharma Trading Down 6.5 %

Lyell Immunopharma stock opened at $0.48 on Monday. The firm has a market capitalization of $142.80 million, a P/E ratio of -0.61 and a beta of -0.41. The stock’s fifty day simple moving average is $0.62 and its 200-day simple moving average is $0.90. Lyell Immunopharma has a twelve month low of $0.48 and a twelve month high of $3.15.

Institutional Trading of Lyell Immunopharma

A number of institutional investors have recently made changes to their positions in the stock. Centiva Capital LP acquired a new stake in shares of Lyell Immunopharma during the third quarter valued at approximately $31,000. Graham Capital Management L.P. acquired a new position in Lyell Immunopharma in the 4th quarter valued at $33,000. RPO LLC acquired a new position in Lyell Immunopharma in the 4th quarter valued at $42,000. Intech Investment Management LLC acquired a new stake in Lyell Immunopharma in the 3rd quarter worth $52,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Lyell Immunopharma in the 3rd quarter worth $52,000. 66.05% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Lyell Immunopharma

In other Lyell Immunopharma news, CEO Lynn Seely bought 175,000 shares of Lyell Immunopharma stock in a transaction that occurred on Friday, March 14th. The shares were acquired at an average price of $0.61 per share, for a total transaction of $106,750.00. Following the acquisition, the chief executive officer now owns 712,500 shares of the company’s stock, valued at $434,625. The trade was a 32.56 % increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Richard Klausner purchased 158,000 shares of the company’s stock in a transaction that occurred on Friday, March 14th. The shares were purchased at an average cost of $0.60 per share, for a total transaction of $94,800.00. Following the purchase, the director now directly owns 843,365 shares in the company, valued at $506,019. This trade represents a 23.05 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 533,000 shares of company stock worth $313,550. Company insiders own 25.10% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.